Why AstraZeneca’s COVID vaccine could be better than the others

AstraZeneca and the University of Oxford have announced the results of the late-stage clinical trials for its COVID vaccine. The headline effective rate is only 70%, but there’s much more to the story. In reality, AstraZeneca’s COVID vaccine could be more promising than the candidates from Pfizer and Moderna.Q3 2020 hedge fund letters, conferences and moreLate-stage results for AstraZeneca’s COVID vaccineWhat makes AstraZeneca’s COVID vaccine trials so different than the trials conducted by Pfizer and Moderna is the fact that the company tried two different dosing regimens. The average effecti…

Read More

HEDGE accordingly